Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Juli 2019 08:00 ET | Quelle: Tyme Technologies, Inc.

REMINDER - TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

In this poor prognosis population, SM-88 demonstrated median overall survival (OS) of 6.4 months as of April 25, 2019 Efficacy indicators showed strong correlation with greater overall survival (OS)....
05. Juli 2019 08:00 ET | Quelle: Tyme Technologies, Inc.

TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

In this poor prognosis population, SM-88 demonstrated median overall survival (OS) of 6.4 months as of April 25, 2019 Efficacy indicators showed strong correlation with greater overall survival (OS)....
07. Juni 2019 08:00 ET | Quelle: Tyme Technologies, Inc.

TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019

SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancersNew oral approach aimed at disrupting cancer metabolism in...
29. Mai 2019 09:09 ET | Quelle: Tyme Technologies, Inc.

TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results

TYME-88-Panc Continues to Show Encouraging Survival Trend with Additional Data to Be Presented in Third Quarter 2019Single Agent SM-88 (Racemetyrosine) Shown to Have Anti-Tumor Response in Preclinical...
29. Mai 2019 07:30 ET | Quelle: Tyme Technologies, Inc.

TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results

TYME-88-Panc Continues to Show Encouraging Survival Trend with Additional Data to Be Presented in Third Quarter 2019Single Agent SM-88 (racemetyrosine) Shown to Have Anti-Tumor Response in Preclinical...
28. Mai 2019 08:00 ET | Quelle: Tyme Technologies, Inc.

Tyme Technologies to Present at the Jefferies 2019 Global Healthcare Conference on June 7, 2019

NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
24. Mai 2019 08:00 ET | Quelle: Tyme Technologies, Inc.

Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019

NEW YORK, May 24, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the company...
23. Mai 2019 08:00 ET | Quelle: Tyme Technologies, Inc.

TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas

New oral approach aimed at disrupting cancer metabolism in high-risk sarcomas; 12,000 cases annually in U.S. aloneSM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy...
20. Mai 2019 08:00 ET | Quelle: Tyme Technologies, Inc.

TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers

NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that it...
09. Mai 2019 08:00 ET | Quelle: Tyme Technologies, Inc.

Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th

NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...

Vorherige Seite